Market Overview:
The global idarubicin hydrochloride market is expected to register a CAGR of 5.5% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of cancer, rising demand for targeted therapies and growing investments in R&D by pharmaceutical companies. Based on type, the global idarubicin hydrochloride market is segmented into 99.6% purity and other types. The 99.6% purity segment is expected to account for a larger share of the market during the forecast period owing to its high quality and efficacy as compared to other types available in the market. Based on application, the global idarubicin hydrochloride market is segmented into oncology and other applications such as cardiology, dermatology etc.).
Product Definition:
Idarubicin Hydrochloride is a chemotherapy drug that is used to treat leukemia, lymphoma, and other types of cancer. It belongs to the class of drugs known as anthracyclines, and works by interfering with the ability of cancer cells to divide and grow.
99.6% Purity:
99.6% purity is a very high level of purity, which means that there are no other components except the Idarubicin Hydrochloride in the final product. Idarubicin Hydrochloride is a dark red crystalline powder and has an odor similar to mustiness. It's appearance is slightly different from other drugs having a darker background color due to its chemical reaction with light (Phosphorescence).
Other:
Other is used in Idarubicin Hydrochloride (IDH) market as an alternative to idarubicin. Other also known as O-Ids or O-Isosorbide diphosphate, is a chemical compound and it’s a natural sugar derivative. It has the same molecular structure like idarubicin but different properties such as solubility, hydrolysis rate, and so on.
Application Insights:
Oncology was the largest application segment in 2017 and accounted for over 50% of total market revenue. Idarubicin is used for the treatment of cancer, either as a single agent or in combination with other drugs. The drug is used to treat various types of cancers such as breast, lung, colorectal and prostate cancer. Increasing incidences leading to an increase in the number of patients diagnosed with cancer has led to increased demand for idarubicin hydrochloride worldwide.
The use of idarubicin hydrochloride as a single agent has resulted in improved response rates and longer survival times among patients suffering from metastatic breast carcinoma; this finding offers hope that the drug may be useful against hard-to-treat cancers such as these (Siegel et al., 2015).
Regional Analysis:
North America accounted for the largest share of global market in 2017. The region is expected to maintain its dominance during the forecast period on account of rising product demand as a result of favorable reimbursement policies and increasing healthcare expenditure. In addition, presence of key manufacturers in this region coupled with high R&D intensity is likely to support growth over the coming years.
Asia Pacific is anticipated to witness lucrative CAGR over the forecast period owing to rapid economic development coupled with government initiatives for improving healthcare infrastructure and provisioning services especially in emerging countries such as China, India, Malaysia & Thailand (CIMT). These factors are expected to boost Idarubicin Hydrochloride market growth during the estimated time span.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the idarubicin hydrochloride market. According to a study by World Health Organization (WHO), it is estimated that around 14 million new cases of cancer were diagnosed in 2012 and this number is expected to rise to 24 million by 2035. This will create a high demand for idarubicin hydrochloride as an anticancer drug.
- Rising awareness about cancer treatments: There has been a rising awareness about various types of cancers and their treatments in recent years. This has led to an increase in the demand for anticancer drugs such as idarubicin hydrochloride.
- Technological advancements in chemotherapy: The technological advancements in chemotherapy have resulted in the development of more effective and safer anticancer drugs such as idarubicin hydrochloride. This is likely to boost the growth of the global idarubicin hydrochloride market over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Idarubicin Hydrochloride Market Research Report
By Type
99.6% Purity, Other
By Application
Oncology, Other
By Companies
Synbias Pharma, Teva API, Zhejiang Hisun Pharmaceutical, DZD(Heze)Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
189
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Idarubicin Hydrochloride Market Report Segments:
The global Idarubicin Hydrochloride market is segmented on the basis of:
Types
99.6% Purity, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Synbias Pharma
- Teva API
- Zhejiang Hisun Pharmaceutical
- DZD(Heze)Pharmaceutical
Highlights of The Idarubicin Hydrochloride Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 99.6% Purity
- Other
- By Application:
- Oncology
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Idarubicin Hydrochloride Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Idarubicin hydrochloride is a chemotherapy drug used to treat cancer. It works by killing cancer cells.
Some of the key players operating in the idarubicin hydrochloride market are Synbias Pharma, Teva API, Zhejiang Hisun Pharmaceutical, DZD(Heze)Pharmaceutical.
The idarubicin hydrochloride market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Idarubicin Hydrochloride Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Idarubicin Hydrochloride Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Idarubicin Hydrochloride Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Idarubicin Hydrochloride Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Idarubicin Hydrochloride Market Size & Forecast, 2020-2028
4.5.1 Idarubicin Hydrochloride Market Size and Y-o-Y Growth
4.5.2 Idarubicin Hydrochloride Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 99.6% Purity
5.2.2 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Oncology
6.2.2 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Idarubicin Hydrochloride Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Idarubicin Hydrochloride Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 99.6% Purity
9.6.2 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Oncology
9.10.2 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 99.6% Purity
10.6.2 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Oncology
10.10.2 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 99.6% Purity
11.6.2 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Oncology
11.10.2 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 99.6% Purity
12.6.2 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Oncology
12.10.2 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 99.6% Purity
13.6.2 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Oncology
13.10.2 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Idarubicin Hydrochloride Market: Competitive Dashboard
14.2 Global Idarubicin Hydrochloride Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Synbias Pharma
14.3.2 Teva API
14.3.3 Zhejiang Hisun Pharmaceutical
14.3.4 DZD(Heze)Pharmaceutical
